

# Supporting Information

## Rerouting the Pathway for the Biosynthesis of the Side Ring System of Nosiheptide: The Roles of NosI, NosJ, and NosK

Edward D. Badding,<sup>†</sup> Tyler L. Grove,<sup>‡,†</sup> Lauren Gadsby,<sup>§</sup> Joseph W. LaMattina,<sup>†</sup> Amie K. Boal,<sup>†,§,\*</sup> and Squire J. Booker<sup>‡,§,#,\*</sup>

<sup>†</sup>The Department of Chemistry, <sup>§</sup>The Department of Biochemistry and Molecular Biology, and <sup>#</sup>The Howard Hughes Medical Institute, The Pennsylvania State University, University Park, Pennsylvania, 16802, USA

The codon-optimized sequence of *nosI*, with the *NdeI* and *EcoRI* restriction sites indicated in bold type.

5'-CACTATAGGGCGAATTGAAGGAAGGCCGTCAAGGCCGAT**CATATGGGTGATATGGG**  
TCGTCCGGCATTTCAGCGTTTCTGACACCGCGTCATCTGCCTGCAGGTCGTGCCGGTGC  
AGTTACCGGGTGTTCGTTGGGTGGTATTTCAGCATGGGATGATCTGCTGACCGCAGG  
TCGCGATCTGGCAGCACAGGTTCGTCCGGGTGGTGCCTATGCAATTGATCCGACAGCAGG  
TCTGCCTGCCCTGGCAGCCCTGTTGCAGTTGCAACCCTGGGATACCGTTCTGCTGTG  
GGCAAGTCCCGTACCCCTGGGTGTTACCGGTCGTGAAATTGCTCCGGACTGCATGCCCT  
GCCGGATGATGGTAGCGTTCCGCTGGCAGCGCAAGAACGTCGCTGTGGGTGTTGTAC  
CAGCGGTAGCAGTGGTGACCGAAAGTTGCAGTTGGTCCGGCAGATGAATGGGAGCAGA  
TTGCCCTGCATGCCGAAGCAGCAATGTATGCAGATGCATTCCGGCAGGTCCGCCTGAAG  
CACTGGCAACCTGTCTGCCGCTGGTTTAGCGCAGCCTTTTATGTGTGTTCTGCCAG  
CACTGTATCTGAAACGTGATCTGGTTGTTCATCCGCCTCATGATTGGAGTCCGCTGTATG  
ATCTGGCACGTGATCGTCGTGTTCTGGCAGTGGGTGTTCCAGCTCTGGCAGCCGCAGCAT  
GTCTGAGCGCACCGGCAAGAACCGATCTGGTAGCGTGCAGTTCTGGTGGTGGTC  
ATCTGAGTGCACCGCGTGTGAACACTGATTGTCGTCACTTACCGGTGCAGCAGTTAGCA  
ATCTGTATGGCACCGCAGAAACCGGTGCAATTGCCCTGGATCACGATCCGGTCATAATC  
GTCATGTTGGTCGTCCGATTCCGGTAAAAGCGTTGGCTGACCGGCACCGATGAACGTG  
GTATTGGCACCGTTGCCGTTGCAGGTCCGGTTGTTGTCGTACCTGGCGTCCGGTA  
GCCCTCCGAGTGCCCTGCAGATCATGTGACCGGTACAGATTATGGTCGTTTGATGCAG  
ATGGTAATCTGTCGTGAAAGGTGCTGGATGGTCAGAAAAACTGGCAGGCAGTCTG  
GTGCGTCCCGTGAAATCGAACGTCATGTGCTGGCCCTGGATGGCGTTAGTGATGTTCGT  
GTTACCGTTGAAACCGCACCGACCGGTCTGGAATTCTGGCAGCGACCGTTGTTGGTAGC  
GTGGATGCAGATACCGTGCACATTGTGCGGCAGTGCAGAACAGCATCGTCCGAGC  
CGTATTAGCTGTGCAAGCGAACAGAACAGCAGCCACCGTTATAGCGCACATGGTAAACTG  
TAAGAATTCCCTGGCCTCATGGGCCTTCCTTCACTGCCGCTTCCAG-3'


The codon-optimized sequence of the *nosJ* gene. The *NdeI* and *EcoRI* restriction sites are indicated in bold type.

5'-CGAATTGGCGGAAGGCCGTCAAGGCCACGTGTCTTGTCCAGAG**CTCCATATGACCAGC**  
CAGCGTACCA**CACACCGCGTACACCGGATGGTGTCCGGATCTGCAAGAAGAACTGGCAGGT**  
CTGCTGCAAGAGGATGATCCCGCGTCGTCTGGATAGCCTGGAAACC**GTTGTTCTGAGCTATTTCGACGT**  
**ACCATTGAAGGTTGGGTTACCTGGCAGATCAGCGTAGCAGCGCAAGCTAAGAATT**CGG  
TACCTGGAGCACAAGACTGGCCTCATGGGCCTCCGCTACTGC-3'


The codon-optimized sequence of *nosK*, with the *NdeI* and *EcoRI* restriction sites indicated in bold type.

5'-  
CGAATTGGCGGAAGGCCGTCAAGGCCACGTGTCTTGTCCAGAG**CTCCATATGGATGCAG**  
AAACCCCGATGGATACCGAAACACCGCGTGATA**ACGGAAACGCCGATGCATACAGGTATGA**  
GCACCGGTCCGAAACACCGACC**GGTTATCTGGTCATGGTCTGCTGGCACCCGGTATG**  
GTCATTTCGACGACAGATT**CGTGCATGGCATGGTCGTCTGCGTACCGTTCCGGTTGATC**  
TGCCTGGTCATGGCGTT**GTGCGATGCAGCCGAAGATTATTTGATGATGCACTGC**  
GTTATCTGGTGGCAGTT**CTGGAACGTTGGTCCGGTCGTCGATTGGTCAAGCTATC**  
TGGGTGGTCCGCTGGCACAT**CGTTGTGCAGCAACCCGTCCGGATCTGGTTAGCAGCCTGG**  
TTCTGACCGGTTTGAC**CCGGATGTTAGCCGTGATGCATTCTGAGCCTGATTGCAGGTT**  
TTGAAGGTCTGGCAGCACAGCAGC**CTGCACTGGCAGCAGAATATGAACAGCTGCATGGCA**  
CCCGTTGGAAAC**GTACCCGTGGATGCAGTTACAGGTATGTTGAACGTGATTGTAACGTA**  
CCGC**ACTGGTTCGTGCAGCAGATGTTGCAGCACTGACCGTTCCGACCCCTGGTGC**TGAATG  
GTAGCCTGAAAAG**CGTGGAACGTCAGGTGAGCCGAGAACAGGCACCGGGTGGGTGGCGT**  
GTT**CGTGGTCGCGTTGTTCCGGGTGAGGTATCTGGTTGGTCATGATCGTCCCGTGAA**  
TTAATGAAGCAGTT**GAAGATTGGCGACCGCACATGATGCACCGGCAGGTCCCGCGT**  
ACCACACAGAAAGGTGATACC**GAATTGGTACCTGGAGCACAAGACTGGCCTCATGGGC**  
CTTCCGCTCACTGC-3'


**Figure S1.** Purification of NosJ. Lanes 1 and 6, molecular mass markers (kDa); lane 2, crude extract; lane 3, pellet; lane 4, flow through from DE-52 column; lane 5, wash from DE-52 column; lane 6, pooled protein from DE-52 column; lane 7, post S-200 column.




**Figure S2.** Purification of NosI. Lane 1, molecular mass markers (kDa); lane 2, pellet; lane 3, crude extract; lane 4, flow through from Talon Co(2<sup>+</sup>) column; lane 5, wash from Talon Co(2<sup>+</sup>) column; lane 6, second wash from Talon Co(2<sup>+</sup>) column; lanes 7 and 8, eluted protein at 2 different concentrations.




**Figure S3.** Overproduction and purification of NosK. Lane 1, molecular mass markers (kDa); lane 2, before IPTG induction; lane 3, after IPTG induction; lane 4, pellet; lane 5, crude extract; lane 6, flow through from Talon Co(2<sup>+</sup>) column; lane 7, wash from Talon Co(2<sup>+</sup>) column; lane 8, second wash from Talon Co(2<sup>+</sup>) column; lanes 9 and 10, eluted protein at 2 different concentrations.



**Figure S4.** Overlay of the catalytic triad acidic residue loop in NosK and valacyclovirase (2OCG PDB accession code).



**Figure S5.** Electrostatic surface potential map for NosK. Surface contoured at  $+ 5 k_B T$  (blue) and  $-5 k_B T$  (red). Corresponding cartoon representations for each view are shown in the bottom panels.



**Table S1.** Fragments from NosK trypsin digestion after treatment with NosJ, NosI, MIA, ATP, CoA, and holo ACP synthase. Highlighted in blue are the peptide fragments containing Ser102.

Sequence	# PSMs	# Proteins	# Protein Groups	Protein Group Accessions	Modifications
DTETPmHTGMSTGPETPTVYLHVGLLGTGHGF AAQIR	8	1	1	C6FX50	M6(Oxidation)
DAFLSIAGFEGLAQQPALAAEYEQLHGTR	101	1	1	C6FX50	
AADVAALTPTVLnGSLK	41	1	1	C6FX50	N15(Deamidated)
DAFLSIAGFEGLAQQdPALAAEYEQLHGTR	3	1	1	C6FX50	Q17(Deamidated)
DTETPMHTGMSTGPETPTVYLHVGLLGTGHGF AAQIR	3	1	1	C6FX50	
DTETPmHTGmSTGPETPTVYLHVGLLGTGHGF AAQIR	11	1	1	C6FX50	M6(Oxidation); M10(Oxidation)
cAATRPDLVSSLVLTGFAPDVS R	61	1	1	C6FX50	C1(Carbamidomethyl)
AADVAALTPTVLN GSLK	47	1	1	C6FX50	
DAFLSIAGFEGLAQQPALAAEYEQLHGTRWK	2	1	1	C6FX50	
FGPGR利GAS YLGGPLAHR	8	1	1	C6FX50	S10(Ser-MIA)
AADVAALTPTVLnGSLKSVER	1	1	1	C6FX50	N15(Deamidated)
EFNEAVEDFWR	82	1	1	C6FX50	
DFERTALVRAADVAALTPTVLN GSLK	2	1	1	C6FX50	
LIGAS YLGGPLAHR	41	1	1	C6FX50	S5(Ser-MIA)
DAAEDYFDDALR	24	1	1	C6FX50	
YLAVAVLERFGPGR利GAS YLGGPLAHR	5	1	1	C6FX50	S18(Ser-MIA)
TALVRAADVAALTPTVLN GSLK	2	1	1	C6FX50	
LIGAS YLGGPLAHRCAATRPDLVSSLVLTGFAPDV SR	5	1	1	C6FX50	
DTETPmHTGmSTGPETPTVYLHVGLLGTGHGF AAQIRAWHGRLR	1	1	1	C6FX50	M6(Oxidation); M10(Oxidation)
AADVAALTPTVLN GSLKSVER	2	1	1	C6FX50	
LIGAS YLGGPLAHRcAATRPDLVSSLVLTGFAPDV SR	3	1	1	C6FX50	C15(Carbamidomethyl)
AAAEQAPGWGGR	5	1	1	C6FX50	
DFERTALVRAADVAALTPTVLnGSLK	3	1	1	C6FX50	N24(Deamidated)
AADVAAALTPTVLN GSLKSVERAAAEQAPGWG GR	3	1	1	C6FX50	
DTETPMHTGmsTGPETPTVYLHVGLLGTGHGF AAqIR	1	1	1	C6FX50	M10(Oxidation); S11(Ser-MIA); Q36(Deamidated)
YLAVAVLER	1	1	1	C6FX50	
TLDAVTG HVER	2	1	1	C6FX50	
TLDAVTG HVERDFER	1	1	1	C6FX50	

**Table S2.** Fragments from NosK trypsin digestion after treatment with NosJ, MIA, ATP, CoA, and holo ACP synthase (NosI omitted). Highlighted in blue are the peptide fragments containing Ser102.

Sequence	# PSMs	# Proteins	# Protein Groups	Protein Group Accessions	Modifications
DAFLSLIAGFEGLAAQQPALAAEYEQLHGTR	116	1	1	C6FX50	
DTETPmHTGmSTGPETPTVYLVHGLLGTGHGF AAqIR	8	1	1	C6FX50	M6(Oxidation); M10(Oxidation)
AADVAALTVPVLNNGSLK	82	1	1	C6FX50	
DAFLSLIAGFEGLAAQQPALAAEYEQLHGTRWK	3	1	1	C6FX50	
AADVAALTVPVLNnGSLK	14	1	1	C6FX50	N15(Deamidated)
cAATRPDLVSSLVLTGFAPDVR	31	1	1	C6FX50	C1(Carbamidomethyl)
DTETPmHTGmSTGPETPTVYLVHGLLGTGHGF AAqIRAWHGR	2	1	1	C6FX50	M6(Oxidation);M10(Oxidation); Q36(Deamidated)
GRVVPAGHLVGHDRPREFNEAVEDFWR	1	1	1	C6FX50	
LIGASYLGGPLAHRcAATRPDLVSSLVLTGFAPDV SR	2	1	1	C6FX50	C15(Carbamidomethyl)
AADVAALTVPVLNNGSLKSVER	3	1	1	C6FX50	
LIGASYLGGPLAHRCAATRPDLVSSLVLTGFAPDV SR	7	1	1	C6FX50	
EFNEAVEDFWR	70	1	1	C6FX50	
AADVAALTVPVLNNGSLKSVERAAAEQAPGWG GR	3	1	1	C6FX50	
DFERTALVRAADVAAALTVPVLNNGSLK	2	1	1	C6FX50	
DAAEDYFDDALR	20	1	1	C6FX50	
AADVAALTVPVLNnGSLKSVER	1	1	1	C6FX50	N15(Deamidated)
DAFLSLIAGFEGLAAQQPALAAEYEQLHGTRWK	3	1	1	C6FX50	
DTETPmHTGmSTGPETPTVYLVHGLLGTGHGF AAqIRAWHGRRL	3	1	1	C6FX50	M6(Oxidation); M10(Oxidation)
DTETPmHTGmSTGPETPTVYLVHGLLGTGHGF AAqIR	1	1	1	C6FX50	M6(Oxidation); M10(Oxidation); Q36(Deamidated)
TALVRAADVAAALTVPVLNNGSLK	2	1	1	C6FX50	
LIGASYLGGPLAHR	1	1	1	C6FX50	
DTETPmHTGmSTGPETPTVYLVHGLLGTGHGF AAqIRAWHGRRL	1	1	1	C6FX50	M6(Oxidation); M10(Oxidation); Q36(Deamidated)
YLAVAVLER	3	1	1	C6FX50	
AAA EQAPGWGR	5	1	1	C6FX50	
AADVAALTVPVLNnGSLKSVERAAAEQAPGWG GR	1	1	1	C6FX50	N15(Deamidated)
DTETPmHTGMSTGPETPTVYLVHGLLGTGHGF AAqIR	5	1	1	C6FX50	M6(Oxidation)
TLDAVTGHVERDFER	1	1	1	C6FX50	
TLDAVTGHVER	2	1	1	C6FX50	

**Table S3. Crystallographic data collection and refinement statistics for NosK (PDB accession code 5V7O)**

<b>Data Collection</b>	
Resolution (Å)	28.00-2.30 (2.38-2.30)
Space group	$P\bar{3}_121$
Cell dimensions	
a, b, c (Å)	75.29, 75.29, 110.12
$\alpha, \beta, \gamma$ (°)	90, 90, 120
Redundancy	10.8 (11.1)
Completeness (%)	99.9 (100)
$I/\sigma I$	13.31 (2.62)
Wilson $B$ -factor (Å <sup>2</sup> )	33.96
$R_{\text{sym}}$	0.040 (0.252)
$R_{\text{pim}}$	0.057 (0.356)
CC <sub>1/2</sub>	0.997 (0.936)
<b>Refinement</b>	
Resolution (Å)	28.00-2.30 (2.38-2.30)
No. reflections	16453
$R_{\text{work}} / R_{\text{free}}$	0.22/0.26
No. atoms	1858
Protein	1762
Ligand/ion	5
Water	230
rms deviations	
bond lengths (Å)	0.007
bond angles (°)	0.87
Ramachandran analysis	
Favored (%)	98
Allowed (%)	2.2
Outliers (%)	0
$B$ -factor (Å <sup>2</sup> )	
Protein	41.84
Ligands/ion	35.19
Water	43.34

Statistics for the highest-resolution shell are shown in parentheses.